Аннотация
В последние 20 лет во всем мире наблюдается повышенный интерес к профилактическому и терапевтическому применению пробиотиков при различных патологических состояниях, однако объем доказательной базы для различных пробиотических микроорганизмов неодинаков. В этом обзоре представлены данные по эффективности двух наиболее хорошо изученных штаммов пробиотиков с установленными положительными эффектами на здоровье человека, а именно Lactobacillus rhamnosus GG и Bifidobacterium lactis Вb-12. Суммированы имеющиеся доказательства эффективности применения пробиотиков для лечения острой диареи, профилактики антибиотик-ассоциированной диареи и нозокомиальных инфекций, применения в качестве дополнительной терапии заболеваний, ассоциированных с H. pylori. Определено место пробиотиков в профилактике инфекций дыхательных путей у детей, рассмотрено лечебное и профилактическое использование пробиотиков при атопическом дерматите и других заболеваниях, приведены практические рекомендации международных обществ по применению пробиотиков. Особое внимание уделено подходам к дозированию и вопросам безопасности использования L. rhamnosus GG и B. lactis Вb-12 в клинической практике, в том числе у уязвимых категорий пациентов.
НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия
НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия
-
1.
Reid G. Regulatory and clinical aspects of dairy probiotics. FAO/ WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina. 2001;1-34.
-
2.
[No authors listed]. World Gastroenterology Organization practice guideline: Probiotics and prebiotics. Arab J Gastroenterol. 2009;10(1):33-42.
DOI: 10.1016/j.ajg.2009.03.001
-
3.
Holzapfel W.H., Haberer P., Geisen R., et al. Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr. 2001;73(2 Suppl):365S-373S.
DOI: 10.1093/ajcn/73.2.365s
-
4.
Salminen S., Benno Y., de Vos W. Intestinal colonisation, microbiota and future probiotics? Asia Pac J Clin Nutr. 2006;15(4):558-562.
-
5.
Silva M., Jacobus N.V., Deneke C., et al. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother. 1987;31(8):1231-1233.
DOI: 10.1128/aac.31.8.1231
-
6.
Gorbach S.L., Goldin B.R. 1989. Lactobacillus strains and methods of selection. US Patent 4839281.
-
7.
Conway P.L., Gorbach S.L., Goldin B.R. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci. 1987;70(1):1-12.
DOI: 10.3168/jds.S0022-0302(87)79974-3
-
8.
Doron S., Snydman D.R., Gorbach S.L. Lactobacillus GG: Bacteriology and clinical applications. Gastroenterol Clin North Am. 2005;34(3):483-498.
DOI: 10.1016/j.gtc.2005.05.011
-
9.
van der Waaij D. Colonization resistance of the digestive tract – mechanism and clinical consequences. Nahrung. 1987;31(5-6):507-517.
-
10.
Douillard F.P., Ribbera A., Kant R., et al. Comparative genomic and functional analysis of 100 Lactobacillus rhamnosus strains and their comparison with strain GG. PLoS Genet. 2013;9(8):e1003683.
DOI: 10.1371/journal.pgen.1003683
-
11.
Petrova M.I., Macklaim J.M., Wuyts S., et al. Comparative Genomic and Phenotypic Analysis of the Vaginal Probiotic Lactobacillus rhamnosus GR-1. Front Microbiol. 2018;9:1278.
DOI: 10.3389/fmicb.2018.01278
-
12.
Marcotte H., Krogh Andersen K., Lin Y., et al. Characterization and complete genome sequences of L. rhamnosus DSM 14870 and L. gasseri DSM 14869 contained in the EcoVag® probiotic vaginal capsules. Microbiol Res. 2017;205:88-98.
DOI: 10.1016/j.micres.2017.08.003
-
13.
Lebeer S., Vanderleyden J., De Keersmaecker S.C. Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev. 2008;72:728-764.
DOI: 10.1128/MMBR.00017-08
-
14.
Lebeer S., Vanderleyden J., De Keersmaecker S.C. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol. 2010;8(3):171-184.
DOI: 10.1038/nrmicro2297
-
15.
Corr S.C., Hill C., Gahan C.G. Understanding the mechanisms by which probiotics inhibit gastrointestinal pathogens. Adv Food Nutr Res. 2009;56:1-15.
DOI: 10.1016/S1043-4526(08)00601-3
-
16.
Mack D.R., Ahrne S., Hyde L., Wei S., et al. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52:827-833.
DOI: 10.1136/gut.52.6.827
-
17.
Rao R.K., Samak G. Protection and Restitution of Gut Barrier by Probiotics: Nutritional and Clinical Implications. Curr Nutr Food Sci. 2013;9(2):99-107.
DOI: 10.2174/1573401311309020004
-
18.
Wells J.M. Immunomodulatory mechanisms of lactobacilli. Microb Cell Fact. 2011;10(Suppl 1):S17.
DOI: 10.1186/1475-2859-10-S1-S17
-
19.
Reid G., Jass J., Sebulski M.T., et al. Potential uses of probiotics in clinical practice. Clin Microbiol Rev. 2003;6(4):658-672.
DOI: 10.1128/cmr.16.4.658-672.2003
-
20.
Guandalini S., Pensabene L., Zikri M.A., et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30(1):54-60.
DOI: 10.1097/00005176-200001000-00018
-
21.
Shornikova A.V., Isolauri E., Burkanova L., et al. A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhea. Acta Paediatr. 1997;86(5):460-465.
DOI: 10.1111/j.1651-2227.1997.tb08913.x
-
22.
Raza S., Graham S.M., Allen S.J., et al. Lactobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan. Pediatr Infect Dis J. 1995;14(2):107-111.
DOI: 10.1097/00006454-199502000-00005
-
23.
Aggarwal S, Upadhyay A1, Shah D, et al. Lactobacillus GG for treatment of acute childhood diarrhoea: an open labelled, randomized controlled trial. Indian J Med Res. 2014;139(3):379-385.
-
24.
Huang J., Bousvaros A., Lee J., et al. Efficacy of probiotic use in acute diarrhea in children, a meta-analysis. Dig Dis Sci. 2002;47(11):2625-2634.
DOI: 10.1023/a:1020501202369
-
25.
Van Niel C.W., Feudtner C., Garrison M.M., et al. Lactobacillus therapy for acute infectious diarrhea in children: a metaanalysis. Pediatrics. 2002;109(4):678-684.
DOI: 10.1542/ peds.109.4.678
-
26.
Allen S.J., Martinez E.G., Gregorio G.V., et al. Probiotics for treating acute infectious diarrhea. Cochrane Database Syst Rev. 2010;11:CD003048.
DOI: 10.1002/14651858.CD003048.pub3
-
27.
Szajewska H., Skorka A., Ruszczynski M., et al. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children – updated analysis of randomised controlled trials. Aliment Pharmacol Ther. 2013;38(5):467-476.
DOI: 10.1111/apt.12403
-
28.
Guarino A., Guandalini S., Lo Vecchio A. Probiotics for Prevention and Treatment of Diarrhea. J Clin Gastroenterol. 2015;49(Suppl 1):S37-45.
DOI: 10.1097/MCG.0000000000000349
-
29.
Ahmadi E., Alizadeh-Navaei R., Rezai M.S. Efficacy of probiotic use in acute rotavirus diarrhea in children: A systematic review and meta-analysis. Caspian J Intern Med. 2015;6(4):187-195.
-
30.
Szajewska H., Kołodziej M., Gieruszczak-Białek D., et al. Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children – a 2019 update. Aliment Pharmacol Ther. 2019;49(11):1376-1384.
DOI: 10.1111/apt.15267
-
31.
WGO Practice Guideline. Probiotics and Prebiotics. World Gastroenterology Organization. 2012. Available at: www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics. Accessed August 15, 2018.
-
32.
Farthing M., Salam M.A., Lindberg G., et al; World Gastroenterology Organization Global Guidelines. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol. 2013;47(1):12-20.
DOI: 10.1097/MCG.0b013e31826df662
-
33.
Szajewska H., Guarino A., Hojsak I., et al; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2014;58(4):531-539.
DOI: 10.1097/MPG.0000000000000320
-
34.
Cameron D., Hock Q.S., Kadim M., et al. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. World J Gastroenterol. 2017;23(45):7952-7964.
DOI: 10.3748/wjg.v23.i45.7952
-
35.
Guarner F., Sanders M.E. Eliakim R., et al.; World Gastroenterology Organization Global Guidelines. Probiotics and prebiotics. February 2017. Available at: www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english. Accessed August 15, 2018.
-
36.
Szajewska H., Kotowska M., Mrukowicz J.Z., et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr. 2001;138(3):361-365.
DOI: 10.1067/mpd.2001.111321
-
37.
Hojsak I., Abdović S., Szajewska H., et al. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics. 2010;125(5):e1171-1177.
DOI: 10.1542/peds.2009-2568
-
38.
Bruzzese E., Fedele M.C., Bruzzese D., et al. Randomised clinical trial: a Lactobacillus GG and micronutrient-containing mixture is effective in reducing nosocomial infections in children, vs. placebo. Aliment Pharmacol Ther. 2016;44(6):568-575.
DOI: 10.1111/apt.13740
-
39.
McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998;16(5):292-307.
DOI: 10.1159/000016879
-
40.
La Rosa M., Bottaro G., Gulino N., et al. [Prevention of antibioticassociated diarrhea with Lactobacillus sporogens and fructooligosaccharides in children. A multicentric double-blind vs placebo study]. Minerva Pediatr. 2003;55(5):447-452.
-
41.
D'Souza A.L., Rajkumar C., Cooke J., et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002;324(7350):1361.
DOI: 10.1136/bmj.324.7350.1361
-
42.
Cremonini F., Di Caro S., Nista E.C., et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002;16(8):1461-1467.
DOI: 10.1046/j.1365-2036.2002.01318.x
-
43.
Johnston B.C., Supina A.L., Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ. 2006;175(4):377-383.
DOI: 10.1503/cmaj.051603
-
44.
Szajewska H., Ruszczyński M., Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr. 2006;149(3):367-372.
DOI: 10.1016/j.jpeds.2006.04.053
-
45.
Johnston B.C., Goldenberg J.Z., Vandvik P.O., et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;11:CD004827.
DOI: 10.1002/14651858.CD004827.pub3
-
46.
Hempel S., Newberry S.J., Maher A.R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-1969.
DOI: 10.1001/jama.2012.3507
-
47.
Goldenberg J.Z., Ma S.S., Saxton J.D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5:CD006095.
DOI: 10.1002/14651858.CD006095.pub3
-
48.
McFarland L.V. Deciphering meta-analytic results: a mini-review of probiotics for the prevention of paediatric antibiotic-associated diarrhoea and Clostridium difficile infections. Benef Microbes. 2015;6(2):189-194.
DOI: 10.3920/BM2014.0034
-
49.
Goldenberg J.Z., Lytvyn L., Steurich J., et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;12:CD004827.
DOI: 10.1002/14651858.CD004827.pub4
-
50.
Szajewska H., Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibioticassociated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42(10):1149-1157.
DOI: 10.1111/apt.13404
-
51.
Jafarnejad S., Shab-Bidar S., Speakman J.R., et al. Probiotics Reduce the Risk of Antibiotic-Associated Diarrhea in Adults (18-64 Years) but Not the Elderly (> 65 Years): A Meta-Analysis. Nutr Clin Pract. 2016;31(4):502-513.
DOI: 10.1177/0884533616639399
-
52.
Goldenberg J.Z., Yap C., Lytvyn L., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12:CD006095.
DOI: 10.1002/14651858.CD006095.pub4
-
53.
Shen N.T., Maw A., Tmanova L.L., et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017;152(8):1889-1900.
DOI: 10.1053/j.gastro.2017.02.003
-
54.
Blaabjerg S., Artzi D.M., Aabenhus R. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients – A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2017;6(4). pii: E21.
DOI: 10.3390/antibiotics6040021
-
55.
Guo Q., Goldenberg J.Z., Humphrey C., et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827.
DOI: 10.1002/14651858.CD004827.pub5
-
56.
Szajewska H., Canani R.B., Guarino A., et al; ESPGHAN Working Group for Probiotics and Prebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016;62(3):495-506.
DOI: 10.1097/MPG.0000000000001081
-
57.
Jarosz M., Rychlik E., Siuba M., et al. Dietary and socioeconomic factors in relation to Helicobacter pylori re-infection. World J Gastroenterol. 2009;15(9):1119-1125.
DOI: 10.3748/wjg.15.1119
-
58.
Gong Y., Li Y., Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a metaanalysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(4):6530-6543.
-
59.
Armuzzi A., Cremonini F., Ojetti V., et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion. 2001;63(1):1-7.
DOI: 10.1159/000051865
-
60.
Tong J.L., Ran Z.H., Shen J., et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155-168.
DOI: 10.1111/j.1365-2036.2006.03179.x
-
61.
Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(5):97-107.
DOI: 10.1111/j.1523-5378.2009.00716.x
-
62.
Wang Z.H., Gao Q.Y., Fang J.Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacteriumcontaining probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32.
DOI: 10.1097/MCG.0b013e318266f6cf
-
63.
Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 2013;105(8):445-453.
DOI: 10.4321/s1130-01082013000800002
-
64.
Li S., Huang X.L., Sui J.Z., et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr. 2014;173(2):153-161.
DOI: 10.1007/s00431-013-2220-3
-
65.
Zhang M.M., Qian W., Qin Y.Y., et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and metaanalysis. World J Gastroenterol. 2015;21(14):4345-4347.
DOI: 10.3748/wjg.v21.i14.4345
-
66.
Lü M., Yu S., Deng J., et al. Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11(10):e0163743.
DOI: 10.1371/journal.pone.0163743
-
67.
Si X.B., Lan Y., Qiao L. A meta-analysis of randomized controlled trials of bismuth-containing quadruple therapy combined with probiotic supplement for eradication of Helicobacter pylori. Zhonghua Nei Ke Za Zhi. 2017;56(10):752-759.
DOI: 10.3760/cma.j.issn.0578-1426.2017.10.009
-
68.
Fang H.R., Zhang G.Q., Cheng J.Y., et al. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr. 2019;178(1):7-16.
DOI: 10.1007/s00431-018-3282-z
-
69.
Shi X., Zhang J., Mo L., et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180.
DOI: 10.1097/MD.0000000000015180
-
70.
Malfertheiner P., Megraud F., O'Morain C.A., et al.; European Helicobacter Study Group Management of Helicobacter pylori infection – the Maastricht IV. Florence Consensus Report. Gut. 2012;61(5):646-664.
DOI: 10.1136/gutjnl-2012-302084
-
71.
Malfertheiner P., Megraud F., O'Morain C.A., et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
DOI: 10.1136/gutjnl-2016-312288
-
72.
Horvath A., Dziechciarz P., Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 2011;33(12):1302-1310.
DOI: 10.1111/j.1365-2036.2011.04665.x
-
73.
Rusu E., Enache G., Cursaru R., et al. Prebiotics and probiotics in atopic dermatitis. Exp Ther Med. 2019;18(2):926-931.
DOI: 10.3892/etm.2019.7678
-
74.
Lin R.J., Qiu L.H., Guan R.Z., et al. Protective effect of probiotics in the treatment of infantile eczema. Exp Ther Med. 2015;9(5):1593-1596.
DOI: 10.3892/etm.2015.2299
-
75.
Isolauri E: Intestinal involvement in atopic disease. J R Soc Med. 1997;90(Suppl 30):15-20.
DOI: 10.1177/0141076897090030s04
-
76.
Penders J., Gerhold K., Thijs C., et al. New insights into the hygiene hypothesis in allergic diseases: Mediation of sibling and birth mode effects by the gut microbiota. Gut Microbes. 2014;5(2):239-244.
DOI: 10.4161/gmic.27905
-
77.
Orivuori L., Mustonen K., de Goffau M.C., et al PASTURE Study Group. High level of fecal calprotectin at age 2 months as a marker of intestinal inflammation predicts atopic dermatitis and asthma by age 6. Clin Exp Allergy. 2015;45(5):928-939.
DOI: 10.1111/cea.12522
-
78.
Schmidt W.P. Model of the epidemic of childhood atopy. Med Sci Monit. 2004;10(2):HY5.
-
79.
Kalliomaki M., Isolauri E. Role of intestinal flora in the development of allergy. Curr Opin Allergy Clin Immunol. 2003;3(1):15-20.
DOI: 10.1097/01.all.0000053262.39029.a1
-
80.
Kalliomaki M., Salminen S., Poussa T., et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361(9372):1869-1871.
DOI: 10.1016/S0140-6736(03)13490-3
-
81.
Rautava S., Kalliomaki M., Isolauri E. Probiotics during pregnancy and breast-feeding might confer immnomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol. 2002;109(1):119-121.
DOI: 10.1067/mai.2002.120273
-
82.
Simpson M.R., Dotterud C.K., Storrø O., et al. Perinatal probiotic supplementation in the prevention of allergy related disease: 6 year follow up of a randomised controlled trial. BMC Dermatol. 2015;15:13.
DOI: 10.1186/s12895-015-0030-1
-
83.
Osborn D.A., Sinn J.K. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007;4:CD006475.
DOI: 10.1002/14651858.CD006475.pub2
-
84.
Lee J., Seto D., Bielory L.J. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. Allergy Clin Immunol. 2008;121(1):116-121.e11.
DOI: 10.1016/j.jaci.2007.10.043
-
85.
Michail S.K., Stolfi A., Johnson T., et al. Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a metaanalysis of randomized controlled trials. Ann Allergy Asthma Immunol. 2008;101(5):508-516.
DOI: 10.1016/S1081-1206(10)60290-6
-
86.
Pelucchi C., Chatenoud L., Turati F., et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012;23(3):402-414.
DOI: 10.1097/EDE.0b013e31824d5da2
-
87.
Doege K., Grajecki D., Zyriax B.C., et al. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood – a meta-analysis. Br J Nutr. 2012;107(1):1-6.
DOI: 10.1017/S0007114511003400
-
88.
Foolad N., Brezinski E.A., Chase E.P., et al. Effect of nutrient supplementation on atopic dermatitis in children: a systematic review of probiotics, prebiotics, formula, and fatty acids. JAMA Dermatol. 2013;149(3):350-355.
DOI: 10.1001/ jamadermatol.2013.1495
-
89.
Elazab N., Mendy A., Gasana J., et al. Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials. Pediatrics. 2013;132(3):e666-676.
DOI: 10.1542/peds.2013-0246
-
90.
Zhang G.Q., Hu H.J., Liu C.Y., et al. Probiotics for Prevention of Atopy and Food Hypersensitivity in Early Childhood: A PRISMACompliant Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 2016;95(8):e2562.
DOI: 10.1097/MD.0000000000002562
-
91.
Huang R., Ning H., Shen M., et al. Probiotics for the Treatment of Atopic Dermatitis in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Cell Infect Microbiol. 2017;7:392.
DOI: 10.3389/fcimb.2017.00392
-
92.
Garcia-Larsen V., Ierodiakonou D., Jarrold K., et al. Diet during pregnancy and infancy and risk of allergic or autoimmune disease: A systematic review and meta-analysis. PLoS Med. 2018;15(2):e1002507.
DOI: 10.1371/journal.pmed.1002507
-
93.
Zhao M., Shen C., Ma L., et al. Treatment efficacy of probiotics on atopic dermatitis, zooming in on infants: a systematic review and meta-analysis. Int J Dermatol. 2018;57(6):635-641.
DOI: 10.1111/ijd.13873
-
94.
Enomoto T., Sowa M., Nishimori K., et al. Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol Int. 2014;63(4):575-585.
DOI: 10.2332/allergolint.13-OA-0683
-
95.
Nwanodi O. Skin protective nutraceuticals: The current evidence in brief. Healthcare (Basel). 2018;6(2):pii: E40.
DOI: 10.3390/healthcare6020040
-
96.
Feleszko W., Jaworska J., Rha R.D., et al. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. Clin Exp Allergy. 2007;37(4):498-505.
DOI: 10.1111/j.1365-2222.2006.02629.x
-
97.
Jang S.O., Kim H.J., Kim Y.J., et al. Asthma prevention by Lactobacillus rhamnosus in a mouse model is associated with CD4(+)CD25(+)Foxp3(+) T cells. Allergy Asthma Immunol Res. 2012;4(3):150-156.
DOI: 10.4168/aair.2012.4.3.150
-
98.
Zheng J., Feng Q., Zheng S., et al. The effects of probiotics supplementation on metabolic health in pregnant women: An evidence based meta-analysis. PLoS One. 2018;13(5):e0197771.
DOI: 10.1371/journal.pone.0197771
-
99.
Schäfer T., Bauer C.P., Beyer K., et al. S3-Guideline on allergy prevention: 2014 update: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Society for Pediatric and Adolescent Medicine (DGKJ). Allergo J Int. 2014;23(6):186-199.
DOI: 10.1007/s40629-014-0022-4
-
100.
Fiocchi A., Pawankar R., Cuello-Garcia C., et al. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. World Allergy Organ J. 2015;8(1):4.
DOI: 10.1186/s40413-015-0055-2
-
101.
Proshutinskaja D.V., Chikin V.V., Znamenskaja L.F. et al. Federal clinical guidelines for the management of patients with atopic dermatitis. Russian Society of Dermatovenerologists and Cosmetologists. Moscow, 2015, 35 p. Russian. (Прошутинская Д.В., Чикин В.В., Знаменская Л.Ф. и соавт. Федеральные клинические рекомендации по ведению больных атопическим дерматитом. Российское общество дерматовенерологов и косметологов. Москва, 2015, 35 с.)
-
102.
Wollenberg A., Barbarot S., Bieber T., et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.
DOI: 10.1111/jdv.14891
-
103.
Collet J.P., Burtin P., Gillet J., еt аl. Risk of infectious diseases in children attending different types of day-care setting. Respiration. 1994;61(Suppl 1):16-19.
DOI: 10.1159/000196375
-
104.
Nafstad P., Hagen J.A., Oie L., et al. Day care centers and respiratory health. Pediatrics. 1999;103(4 Pt 1):753-758.
DOI: 10.1542/peds.103.4.753
-
105.
Hatakka K., Savilahti E., Ponka A., et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ. 2001;322(7298):1327.
DOI: 10.1136/bmj.322.7298.1327
-
106.
Hojsak I., Snovak N., Abdović S., et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, doubleblind, placebo-controlled trial. Clin Nutr. 2010;29(3):312-316.
DOI: 10.1016/j.clnu.2009.09.008
-
107.
Rautava S., Arvilommi H., Isolauri E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res. 2006;60(2):221-224.
DOI: 10.1203/01.pdr.0000228317.72933.db
-
108.
Rautava S., Salminen S., Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, doubleblind, placebo-controlled study. Br J Nutr. 2009;101(11):1722-1726.
DOI: 10.1017/S0007114508116282
-
109.
Taipale T.J., Pienihäkkinen K., Isolauri E., et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in early childhood. Pediatr Res. 2016;79(1-1):65-69.
DOI: 10.1038/pr.2015.174
-
110.
Hao Q., Dong B.R., Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015;2:CD006895.
DOI: 10.1002/14651858.CD006895.pub3
-
111.
Amaral M.A., Guedes G., Epifanio M., et al. Network metaanalysis of probiotics to prevent respiratory infections in children and adolescents. Pediatr Pulmonol. 2017;52(6):833-843.
DOI: 10.1002/ppul.23643
-
112.
Lenoir-Wijnkoop I., Gerlier L., Roy D., et al. The Clinical and Economic Impact of Probiotics Consumption on Respiratory Tract Infections: Projections for Canada. PLoS One. 2016;11(11):e0166232.
DOI: 10.1371/journal.pone.0166232
-
113.
Loesche W.J. Microbiology of dental decay and periodontal disease. In: Baron’s Medical Microbiology. 4th Ed. University of Texas Medical Branch; 1996.
-
114.
Näse L., Hatakka K., Savilahti E., et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001;35(6):412-420.
DOI: 10.1159/000047484
-
115.
Alanzi A., Honkala S., Honkala E., et al. Effect of Lactobacillus rhamnosus and Bifidobacterium lactis on gingival health, dental plaque, and periodontopathogens in adolescents: a randomised placebo-controlled clinical trial. Benef Microbes. 2018;9(4):593-602.
DOI: 10.3920/BM2017.0139
-
116.
Lee Y.K., Salminen S. The Coming of Age of Probiotics. Trends in Food Science & Technology. 1995;6:241-245.
DOI: 10.1016/S0924-2244(00)89085-8
-
117.
Hamilton-Miller J. Probiotics – panacea or nostrum? BNF Nutrition Bulletin. 1996;21:199-208.
DOI: 10.1111/j.1467-3010.1996.tb00853.x
-
118.
Basu S., Chatterjee M., Ganguly S., et al. Effect of Lactobacillus rhamnosus GG in persistent diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol. 2007;41(8):756-760.
DOI: 10.1097/01.mcg.0000248009.47526.ea
-
119.
Basu S., Paul D.K., Ganguly S., et al. Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol. 2009;43(3):208-213.
DOI: 10.1097/MCG.0b013e31815a5780
-
120.
Kligler B., Cohrssen A. Probiotics. Am Fam Physician. 2008;78(9):1073-1078.
-
121.
Guidelines for the Evaluation of Probiotics in Food. Joint FAO/ WHO (Food and Agriculture Organization/World Health Organisation) Working Group. London, Ontario, Canada: 2002.
-
122.
Marteau P. Safety aspects of probiotic products. Scand J Nutr. 2001;45:22-24.
DOI: 10.3402/fnr.v45i0.1785
-
123.
Mackay A.D., Taylor M.B., Kibbler C.C., et al. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect. 1999;5(5):290-292.
DOI: 10.1111/j.1469-0691.1999.tb00144
-
124.
Rautio M., Jousimies-Somer H., Kauma H., et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis. 1999;28(5):1159-1160.
DOI: 10.1086/514766
-
125.
Salminen M.K., Rautelin H., Tynkkynen S., et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38(1):62-69.
DOI: 10.1086/380455
-
126.
Land M.H., Rouster-Stevens K., Woods C.R., et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;115(1):178-181.
DOI: 10.1542/peds.2004-2137
-
127.
De Groote M.A., Frank D.N., Dowell E., et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J. 2005;24(3):278-280.
DOI: 10.1097/01.inf.0000154588.79356.e6
-
128.
Robin F., Paillard C., Marchandin H., et al. Lactobacillus rhamnosus meningitis following recurrent episodes of bacteremia in a child undergoing allogeneic hematopoietic stem cell transplantation. J Clin Microbiol. 2010;48(11):4317-4319.
DOI: 10.1128/JCM.00250-10
-
129.
Luong M.L., Sareyyupoglu B., Nguyen M.H., et al. Lactobacillus probiotic use in cardiothoracic transplant recipients: a link to invasive Lactobacillus infection? Transpl Infect Dis. 2010;12(6):561-564.
DOI: 10.1111/j.1399-3062.2010.00580.x
-
130.
Gouriet F., Million M., Henri M., et al. Lactobacillus rhamnosus bacteremia: an emerging clinical entity. Eur J Clin Microbiol Infect Dis. 2012;31(9):2469-2480.
DOI: 10.1007/s10096-012-1599-5
-
131.
Vahabnezhad E., Mochon A.B., Wozniak L.J., et al. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47(5):437-439.
DOI: 10.1097/MCG.0b013e318279abf0
-
132.
Falci D.R., Rigatto M.H., Cantarelli V.V., et al. Lactobacillus rhamnosus bacteremia in a kidney transplant recipient. Transpl Infect Dis. 2015;17(4):610-612.
DOI: 10.1111/tid.12410
-
133.
Meini S., Laureano R., Fani L., et al. Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature. Infection. 2015;43(6):777-781.
DOI: 10.1007/s15010-015-0798-2
-
134.
Ambesh P., Stroud S., Franzova E., et al. Recurrent Lactobacillus Bacteremia in a Patient With Leukemia. J Investig Med High Impact Case Rep. 2017;5(4):2324709617744233.
DOI: 10.1177/2324709617744233
-
135.
Zeba F., Yirerong J., Assali M., et al. A Double Whammy: Lactobacillus acidophilus Bacteremia and Subsequent Lactobacillus rhamnosus Prosthetic Valve Infective Endocarditis in an Elderly Diabetic Patient. R I Med J (2013). 2018;101(9):32-33.
-
136.
Naqvi S.S.B., Nagendra V., Hofmeyr A. Probiotic related Lactobacillus rhamnosus endocarditis in a patient with liver cirrhosis. IDCases. 2018;13:e00439.
DOI: 10.1016/j.idcr.2018.e00439
-
137.
Koyama S., Fujita H., Shimosato T., et al. Septicemia from Lactobacillus rhamnosus GG, from a Probiotic Enriched Yogurt, in a Patient with Autologous Stem Cell Transplantation. Probiotics Antimicrob Proteins. 2019;11(1):295-298.
DOI: 10.1007/s12602-018-9399-6
-
138.
Salminen M.K., Tynkkynen S., Rautelin H., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002;35(10):1155-1160.
DOI: 10.1086/342912
-
139.
Ouwehand A.C., Saxelin M., Salminen S. Phenotypic differences between commercial Lactobacillus rhamnosus GG and L. rhamnosus strains recovered from blood. Clin Infect Dis. 2004;39(12):1858-1860.
DOI: 10.1086/425741
-
140.
Hempel S., Newberry S., Ruelaz A., et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep). 2011;200:1-645.
-
141.
van den Nieuwboer M., Claassen E., Morelli L., et al. Probiotic and synbiotic safety in infants under two years of age. Benef Microbes 2014;5(1):45-60.
DOI: 10.3920/BM2013.0046
-
142.
van den Nieuwboer M., Brummer R.J., Guarner F., et al. Safety of probiotics and synbiotics in children under 18 years of age. Benef Microbes 2015;6(5):615-630.
DOI: 10.3920/BM2014.0157
-
143.
Van den Nieuwboer M., Brummer R.J., Guarner F., et al. The administration of probiotics and synbiotics in immune compromised adults: is it safe? Benef Microbes 2015;6(1):3-17.
DOI: 10.3920/BM2014.0079
-
144.
Dugoua J.J., Machado M., Zhu X., et al. Probiotic safety in pregnancy: a systematic review and meta-analysis of randomized controlled trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp. J Obstet Gynaecol Can 2009;31(6):542-552.
DOI: 10.1016/S1701-2163(16)34218-9
-
145.
Besselink M.G., van Santvoort H.C., Buskens E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9613): 651-659.
DOI: 10.1016/S0140-6736(08)60207-X
-
146.
Williams N.T. Probiotics. Am J Health Syst Pharm. 2010;67(6):449-458.
DOI: 10.2146/ajhp090168
-
147.
Stadlbauer V. Immunosuppression and probiotics: are they effective and safe? Benef Microbes. 2015;6(6):823-828.
DOI: 10.3920/BM2015.0065
-
148.
Cohen S.A., Woodfield M.C., Boyle N., et al. Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations. Transpl Infect Dis. 2016;18(5):699-705.
DOI: 10.1111/tid.12587
-
149.
Ladas E.J., Bhatia M., Chen L., et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51(2):262-266.
DOI: 10.1038/bmt.2015.275
-
150.
Sadanand A., Newland J.G., Bednarski J.J. Safety of Probiotics Among High-Risk Pediatric Hematopoietic Stem Cell Transplant Recipients. Infect Dis Ther. 2019;8(2):301-306.
DOI: 10.1007/s40121-019-0244-3